Keyphrases
Canine Osteosarcoma
100%
MicroRNA
100%
Cell Death
100%
Human Osteosarcoma
100%
Chromatin
100%
Combinational Therapy
100%
Osteosarcoma Cell Lines
100%
Osteosarcoma
66%
C-Myc
66%
14q32 Locus
66%
Histone Deacetylase Inhibitor (HDACi)
33%
4-phenylbutyrate
33%
DNA Methylation (DNAm)
33%
Vorinostat
33%
Apoptosis Induction
33%
Attenuation
33%
Cytotoxicity
33%
Acetylation
33%
Suberoylanilide Hydroxamic Acid
33%
Pathobiology
33%
Histone
33%
Molecular Phenotype
33%
Genome-wide Expression
33%
Rapidly Progressive
33%
Gene Expression Changes
33%
Cell Cycle Genes
33%
Promoter Region
33%
Osteosarcoma Cells
33%
Apoptotic Genes
33%
5-azacytidine
33%
Concomitant Treatment
33%
Differential Methylation
33%
MiRNA Expression
33%
DNA Methyltransferase Inhibitor
33%
Saos-2
33%
MiRNA Cluster
33%
Zebularine
33%
Recurrent Patterns
33%
Aggressive Biological Behavior
33%
Histone Deacetylase Activity
33%
Neuroscience
MicroRNA
100%
Cell Line
100%
Cell Death
100%
Osteosarcoma
100%
DNA Methylation
40%
Behavior (Neuroscience)
20%
Methylation
20%
Cytotoxicity
20%
Histone Deacetylase
20%
Zebularine
20%
Vorinostat
20%
Gene Expression
20%
Histone
20%
Promoter Region
20%
Cell Cycle
20%
Hydroxamic Acid
20%
Acetylation
20%
Histone Deacetylase Inhibitor
20%
Azacitidine
20%
Immunology and Microbiology
down Regulation
100%
Cell Death
100%
Osteosarcoma Cell Line
100%
DNA Methylation
66%
Cytotoxicity
33%
Gene Expression
33%
Promoter Region
33%
Osteosarcoma Cell
33%
Cell Cycle
33%
Methylation
33%
Acetylation
33%
Biochemistry, Genetics and Molecular Biology
MicroRNA
100%
Cell Death
100%
down Regulation
60%
DNA Methylation
40%
Histone Deacetylase
40%
Acetylation
20%
Methylation
20%
Histone
20%
Zebularine
20%
Gene Expression
20%
Cell Cycle
20%
Cytotoxicity
20%
Pribnow Box
20%
Azacitidine
20%
Saos-2 Cells
20%
Pharmacology, Toxicology and Pharmaceutical Science
Osteosarcoma
100%
microRNA
100%
Vorinostat
60%
Cytotoxicity
20%
Histone Deacetylase Inhibitor
20%
Sodium Phenylbutyrate
20%
Azacitidine
20%
Histone
20%
Histone Deacetylase
20%
Zebularine
20%